Accelleron Industries AG General Assembly 2023: All Proposals Receive Approval
The shareholders of Accelleron Industries AG have approved all proposals of the Board of Directors with a large majority on the occasion of the first Annual General Meeting today.
At the first Annual General Meeting of Accelleron Industries AG, the shareholders approved all proposals, including the total maximum aggregate of compensation for the members of the Board of Directors for the period from the Annual General Meeting 2023 to the Annual General Meeting 2024 and the maximum aggregate amount of compensation for the members of the Executive Committee for the financial year 2024, in each case by a large majority.
The proposed dividend for the financial year 2022 was approved by a large majority. Shareholders will receive a distribution in the form of a dividend of CHF 0.73 gross per share.
All the proposed members of the Board of Directors were confirmed. Oliver Riemenschneider was re-elected as Chairman of the Board of Directors with a large majority. A total of 55,863,682 registered shares with voting rights were represented at the Annual General Meeting of Accelleron Industries AG, representing 59.12 % of the share capital entered in the share register with voting rights.
Accelleron is a leading global supplier of turbochargers and optimization solutions for engines from 0.5 to 80+ MW, helping to provide sustainable, efficient and reliable energy to the marine, energy, rail and off-highway sectors. Through its innovative product offering and research leadership, the company is accelerating the decarbonization of the industries in which it operates. Accelleron has an installed base of approximately 180,000 turbochargers and a network of more than 100 service stations in 50 countries worldwide (www.accelleron-industries.com).
| Important data |
|
| May 23, 2023 |
Ex date for dividend payment |
| May 25, 2023 |
Distribution of the dividend |
| September 5, 2023 |
Publication of half-year report 2023 |
Information for the media
Images and other digital content are available at www.accelleron-industries.com.
Accelleron sharesThe registered shares of Accelleron Industries AG are listed on the SIX Swiss Exchange, Zurich, under the ticker symbol "ACLN" (ISIN: CH1169360919 / Swiss security number: 116936091).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509006003/en/
Contact information
Contact for the media:
Martin Regnet
Head of External Communications and Public Affairs
media@accelleron-industries.com
Phone: +41 79 627 63 88
Contact for investors:
Michael Daiber
Vice President Strategy & IR
investors@accelleron-industries.com
Phone: +41 79 698 6085
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries7.5.2024 08:00:00 EEST | Press release
Galderma today announced that it has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia, Singapore, Switzerland, and the United Kingdom, whose regulatory authorities are members of the Access Consortium. An approval decision is expected from the consortium next year. Nemolizumab is a therapy specifically inhibiting IL-31 signaling to provide safe and rapid relief from the most burdensome symptom of both skin conditions: itch.1-7 The Access Consortium is a collaborative initiative comprised of regulatory authorities which work together to address shared challenges, sharing knowledge and promoting greater collaboration to make regulatory systems more efficient.8 These acceptances are in addition to those received from the U.S. Food and Drug Administration (FDA) and European Medicines Agency for nemolizumab for the treatment of prurigo nodularis and atopic de
IFF Reports First Quarter 2024 Results7.5.2024 00:27:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2024. Management Commentary "We have started the year well, with good results across the majority of our business," said IFF CEO Erik Fyrwald. "In the first quarter, we delivered volume growth and productivity gains, which resulted in solid top-and-bottom-line results on a comparable basis. We are off to a good start, yet recognize that it is still early in the year and uncertainty remains. Based on our performance to date and our outlook for the balance of the year, we believe results will likely trend towards the higher-end of our previously announced guidance ranges. We also took important steps in our portfolio optimization strategy by reaching an agreement to sell our Pharma Solutions business and completing the previously announced divestiture of our Cosmetic Ingredients business. These actions, along with the rightsizing of our dividend earlier this year, represent significant steps toward our commi
IFF Chief Financial and Business Transformation Officer Glenn Richter to retire year end 20246.5.2024 23:16:00 EEST | Press release
IFF (NYSE: IFF) today announced that Glenn Richter, IFF’s Chief Financial and Business Transformation Officer, plans to retire Dec. 31, 2024 after a three-year tenure with the company. A succession process has been initiated to evaluate internal and external candidates to succeed Richter as CFO. “During his time at IFF, Glenn has driven multiple actions to improve our balance sheet and position the company for financial success,” said Erik Fyrwald, IFF CEO. “We have benefited from his experience and commitment to transformation. Notably, the work he has led on portfolio optimization, strategy development and our shared services agenda have positioned IFF to drive long-term profitable market share growth. The Board and I are grateful for all Glenn has helped IFF accomplish, and we appreciate his ongoing leadership of the finance function and support in identifying his successor and ensuring a smooth transition.” Richter has been with IFF since 2021, leading global finance. Before joinin
The Empire State Building Partners with Outward Bound on First-Ever, Full Rappel Down the Building for Charity6.5.2024 21:34:00 EEST | Press release
The Empire State Building (ESB) hosted 20 brave supporters of Outward Bound – along with participant Jared Leto – in a historic rappel down the building’s south façade, in partnership with Outward Bound to raise transformational funds for the charity across the world. Participants total donations exceeded $3 million to Outward Bound, which will make a profound difference in the educational journeys of young people everywhere. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240506846659/en/ The Empire State Building Partners with Outward Bound on First-Ever, Full Rappel Down the Building for Charity (Photo: Business Wire) “The Empire State Building is the perfect host to amplify Outward Bound’s charitable mission through this historic rappel, and it reaffirms the Empire State Building’s long-held status as a symbol of hope, strength, and resilience,” said Tony Malkin, chairman and CEO of Empire State Realty Trust. “My wife and
Armis Wins 6 Global InfoSec Awards at RSAC 2024, Named “Hot” Cybersecurity Company6.5.2024 19:10:00 EEST | Press release
Armis, the asset intelligence cybersecurity company, today announced that it has won six Global InfoSec Awards from Cyber Defense Magazine at this year’s RSA Conference. Armis received the following accolades: Armis named “Hot Cybersecurity Company” Nadir Izrael, Armis’ Co-Founder and CTO, awarded “Cutting Edge Chief Technology Officer” Armis Centrix™ won multiple awards: “Cutting Edge” platform accolade in the Cyber Exposure Management category “Best Product” for Attack Surface Management “Next Gen” product for Vulnerability Prioritization and Remediation The Armis AI-powered Asset Intelligence Engine received a “Publisher’s Choice” award in the category recognizing AI Platforms for Cybersecurity Strategy Analytics “These accolades reinforce Armis’ dedication to innovation and our commitment to helping our customers solve their biggest cybersecurity problems through one comprehensive platform,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Armis will continue to push the boundari
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom